Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements.
Net profit-273 millionEGP · −256.8% vs the same period a year earlier
Total assets514 millionEGP · −39.5% vs the same period a year earlier
Shareholders' equity94.33 millionEGP · −79.6% vs the same period a year earlier
Operating cash flow-38.01 millionEGP · −128.2% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q4 2023 was about -273 million EGP, down −256.8% from 174 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 514 million EGP, and shareholders' equity about 94.33 million EGP.
- Operating cash flow for Q4 2023 was negative at 38.01 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit-273 million174 million−256.8%
Gross profit313 million576 million−45.7%
Total assets514 million850 million−39.5%
Total liabilities419 million387 million+8.4%
Shareholders' equity94.33 million463 million−79.6%
Total liabilities and equity514 million850 million−39.5%
Operating cash flow-38.01 million135 million−128.2%
Investing cash flow-4.42 million-6.01 million+26.5%
Financing cash flow-69.02 million-2.5 million−2665.5%
Net change in cash46.33 million126 million−63.4%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy